These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12562663)

  • 41. Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
    Westermann AM; ten Bokkel Huinink WW; Rodenhuis S
    Ann Oncol; 1996 Jan; 7(1):104. PubMed ID: 9081381
    [No Abstract]   [Full Text] [Related]  

  • 42. Response to dexamethasone in patients with fluid retention after docetaxel.
    Chan S; Winterbottom L; Gardner S
    Lancet; 1996 May; 347(9013):1486-7. PubMed ID: 8676655
    [No Abstract]   [Full Text] [Related]  

  • 43. Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
    Aapro MS
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):1-2. PubMed ID: 7740325
    [No Abstract]   [Full Text] [Related]  

  • 44. Docetaxel. A review of its role in breast cancer treatment.
    Antoine EC; Rixe O; Auclerc G; Weil M; Khayat D
    Am J Clin Oncol; 1997 Aug; 20(4):429-32. PubMed ID: 9256905
    [No Abstract]   [Full Text] [Related]  

  • 45. Docetaxel (Taxotere) for advanced breast cancer.
    Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
    [No Abstract]   [Full Text] [Related]  

  • 46. [Current developments in use of docetaxel (taxotere) in gynecologic oncology].
    Jackisch C
    Med Klin (Munich); 1998 Sep; 93 Suppl 3():4-15. PubMed ID: 9796219
    [No Abstract]   [Full Text] [Related]  

  • 47. [Role of docetaxel in the treatment of gastric cancer].
    Cascinu S
    Tumori; 2001; 87(6):A10-2. PubMed ID: 11995696
    [No Abstract]   [Full Text] [Related]  

  • 48. Docetaxel.
    Leahy M; Howell A
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
    Dourakis SP; Sevastianos VA; Alexopoulou A; Deutsch M; Stavrianeas N
    J Clin Oncol; 2002 Jul; 20(13):3030-2. PubMed ID: 12089234
    [No Abstract]   [Full Text] [Related]  

  • 50. [Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
    Schneeweiss A; Lenz F; Beldermann F; Geberth M; Goerner R; Solomayer E; Bastert G
    Zentralbl Gynakol; 2001 Sep; 123(9):520-8. PubMed ID: 11709745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxoids: new weapons against cancer.
    Nicolaou KC; Guy RK; Potier P
    Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
    [No Abstract]   [Full Text] [Related]  

  • 52. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The development of docetaxel (Taxotere) in non-small cell lung cancer.
    Kris MG; Miller VA; Ng KK; Grant SC
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
    [No Abstract]   [Full Text] [Related]  

  • 54. Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer.
    Oncology (Williston Park); 1996 Mar; 10(3):422. PubMed ID: 8820455
    [No Abstract]   [Full Text] [Related]  

  • 55. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
    Lokich J; Anderson N
    Ann Oncol; 1998 May; 9(5):573. PubMed ID: 9653501
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
    Yorulmaz A; Dogan M; Artuz F; Zengin N
    Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
    Kouroussis C; Samonis G; Androulakis N; Souglakos J; Voloudaki A; Dimopoulos MA; Kotsakis T; Kakolyris S; Kalbakis K; Georgoulias V
    Am J Clin Oncol; 2000 Jun; 23(3):309-13. PubMed ID: 10857900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
    Verweij J; Clavel M; Chevalier B
    Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison.
    Johnson K; Stoffel B; Schwitter M; Hayoz S; Rojas Mora A; Fischer Maranta A; El Saadany T; Hasler U; von Moos R; Patzen A; Mark M; Roberts G; Cathomas R
    Support Care Cancer; 2024 Jul; 32(8):554. PubMed ID: 39066890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II trial of docetaxel in advanced non-small cell lung cancer.
    Saarinen A; Jekunen A; Halme M; Pyrhönen S; Tamminen K; Boyer R; Roubille N; Mattson K
    Anticancer Drugs; 1996 Nov; 7(8):890-2. PubMed ID: 8991195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.